RxDoctor Payments Data

Alan Jonas

Psychiatry · Baltimore, MDNPI 1467552521

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $14,950 of the $19,957 with a category attached, or 74.9%. Johnson & Johnson accounts for 92.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $13,567 and has fallen 99.4% since, to $79 in 2024. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,957in general payments, 2019–2025

Across 130 payments — averaging $153.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$18K
  • Corium, LLC$424
  • AbbVie$212
  • Takeda Pharmaceuticals U.S.A., Inc.$128
  • Amgen$125
  • Neos Therapeutics, LP$109
  • plus $528 from 14 others
$1,055,034in research payments, 2019–2025

Across 104 payments — averaging $10,145 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$495K
  • Eli Lilly$277K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$224K
  • Alkermes, Inc.$34K
  • Sage Therapeutics, LLC$14K
  • Takeda Pharmaceuticals U.S.A., Inc.$10K
  • plus $2K from 2 others

What the payments were for

  • Speaking & faculty fees$14,95075%
  • Travel & lodging$2,80714%
  • Food & beverage$2,15311%
  • Education$470%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,957 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.

See all psychiatry providers in Maryland

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide11$15,264
Venlafaxine Hcl ErVenlafaxine Hcl21$871
Clonazepam74$602
Bupropion XlBupropion Hcl18$569
Fluoxetine Hcl21$544
Clozapine11$451
Mirtazapine13$437
Risperidone11$360
Benztropine Mesylate11$295
Escitalopram Oxalate21$241
Lorazepam30$189
Lamotrigine13$186
Trazodone Hcl13$182
Sertraline Hcl12$155
Zolpidem Tartrate ErZolpidem Tartrate13$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$128$15,26411 claims
Almatica Pharma LLCSertraline Hcl$74$15512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 851 psychiatry providers in Maryland.

Other psychiatry in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →